A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (Industry)

Overall Status

Completed

CT.gov ID

NCT00309686

Collaborator

(none)

300

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while they are taking lithium or valproate. This study will also evaluate the effect of paliperidone ER compared with placebo on overall functioning, on how quickly a response is seen, on improvement in severity of illness, on health-related functional status, on depressive symptoms, and on psychotic symptoms. The relationship between blood levels and the effectiveness and safety of paliperidone ER will be evaluated, including the effect of food relative to time of taking the drug.

Condition or Disease	Intervention/Treatment	Phase
Affective Psychosis, Bipolar Bipolar Disorder Mania	Drug: Paliperidone ER	Phase 3

Detailed Description

Several treatments are available for the treatment of acute manic and mixed episodes associated with bipolar disorder. Some of these treatments, including lithium, divalproex sodium, and carbamazepine, have been used for many years. More recently, risperidone and a number of atypical antipsychotics (olanzapine, quetiapine, ziprasidone, aripiprazole) have been approved for use in the treatment of acute mania. Paliperidone has similar properties to risperidone and is thus expected to have at least similar efficacy to risperidone in the treatment of acute manic and mixed episodes associated with bipolar disorder. Paliperidone ER has been shown to be effective in treating schizophrenia, and has an improved delivery system (with delivery at a relatively controlled rate over 24 hours) and a reduced potential for drug-drug interactions. Treatment of bipolar mania often involves more than a single medication. Studies of mood stabilizers in combination with antipsychotic agents have suggested greater efficacy or more rapid onset of action with these combinations than with any of these agents alone. It is therefore of interest to evaluate the effectiveness of paliperidone ER in combination with mood stabilizers for the treatment of acute manic and mixed episodes associated with bipolar disorder.

This randomized (patients are randomly assigned to receive paliperidone ER or placebo), double-blind (neither the patient nor the physician knows whether drug or placebo and what dosage is being taken), placebo-controlled, parallel-group, multicenter study will evaluate paliperidone ER compared with placebo over a 6-week period in patients with Bipolar I Disorder who are experiencing an acute manic or mixed episode and are taking lithium or valproate. A flexible dosing regimen will be used in this study to afford investigators the ability to adjust the dosage of each subject to achieve rapid control of acute manic symptoms. After a screening/washout phase of no more than 7 days to determine if patients are eligible and to discontinue all medications excluded per protocol criteria(including any mood-stabilizing medications other than lithium or valproate), patients will be randomly assigned to either paliperidone ER or placebo for a 6-week, double-blind treatment phase. Patients will be hospitalized for at least the first 7 days, and will be discharged and followed as outpatients only if they are considered to be at no significant risk of violent or suicidal behavior. An end-of-study visit will be conducted at the end of the double-blind treatment phase or at early withdrawal, whichever comes first. A follow-up (post-treatment) visit for safety evaluations will be scheduled approximately 1 week after the end-of-study/early withdrawal visit. The study, including the screening/washout phase, will last up to 56 days (8 weeks).

Effectiveness will primarily be determined by the change from baseline in the Young Mania Rating Scale (YMRS) score to the end of the 6-week double-blind treatment phase or early withdrawal. The YMRS is an established 11-item scale used to evaluate manic symptoms. A secondary measure of effectiveness will be the change from baseline in the Global Assessment of Functioning (GAF) score to the end of the 6 weeks of treatment. Additional measures of effectiveness will measure severity of bipolar illness, psychotic symptoms, quality of sleep, and health-related functional status. Safety will be measured by monitoring the frequency, severity, and timing of side effects; monitoring the need for additional medications; clinical laboratory tests (including pregnancy tests), 12-lead electrocardiograms; measurement of vital signs (blood pressure, pulse, and temperature); and physical examination (including height, weight, and waist circumference). Three scales will be used to assess specific neurologic side effects; the Scale for Suicidal Ideation will be used to evaluate any suicidal tendencies. The primary study hypothesis is that, in the treatment of patients who experience an acute manic or mixed episode while they are taking lithium or valproate for the treatment of Bipolar I Disorder, paliperidone ER is superior to placebo on the change from baseline in the YMRS total score at the end of 6 weeks of double-blind treatment. The secondary hypothesis is that, in these same patients, paliperidone ER is superior to placebo on the change from baseline in GAF score at the end of 6 weeks of double-blind treatment. Flexibly dosed oral paliperidone ER (3 to 12 mg/day) or matching placebo once daily. All study drug will be administered before 10:00 a.m. Initial dosage will be 6 mg/day; adjustment of the dosage will be based on assessment of the patient's response to and tolerance of the study drug. Dosage may be increased in 3-mg/day increments or decreased as deemed necessary; dosage should only be increased every 2 days unless a patient requires a higher dosage to control manic symptoms.

Study Design

Study Type:

Interventional

Actual Enrollment :

300 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder

Study Start Date :

Apr 1, 2006

Actual Study Completion Date :

Aug 1, 2007

Outcome Measures

Primary Outcome Measures

The primary effectiveness outcome is the change in total YMRS score from baseline (first dose) to the last assessment in the 6-week double-blind treatment phase. []

Secondary Outcome Measures

The secondary effectiveness outcome is the change in GAF score from baseline (first dose) to the last assessment in the 6-week double-blind treatment phase. []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Meets Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria for Bipolar I Disorder, Most Recent Episode Manic or Mixed (with or without psychotic features)
History of at least 1 previously documented manic or mixed episode requiring medical treatment within the past 3 years
Must have been taking lithium or valproate as part of treatment for Bipolar I Disorder for at least 2 weeks before screening, with drug levels at screening within therapeutic range
Total YMRS score of at least 20 at screening and at baseline (Day 1)
Women must be postmenopausal for at least 2 years or agree to practice an effective method of birth control throughout the study.

Exclusion Criteria:

Meets DSM-IV criteria for rapid cycling and schizoaffective disorder
In the opinion of the study doctor, is at significant risk for suicidal or violent behavior during the course of the study
Has used cocaine, phencyclidine, amphetamine, methylphenidate, pemoline, an opioid (excluding codeine), hallucinogen, or any other drug that may be associated with manic symptoms as evidenced by a positive urine drug screen
Has received benzodiazepines at doses equal to 4 mg/day of lorazepam or higher for a period of 3 months or longer immediately before the screening phase.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Investigators

Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.